There are two common isoforms of the CXCR3 receptor, CXCR3 A and CXCR3 B. Overall, CXCR3 is associated with cancer progression by altering the TME, but also with anti-tumor effects and growth reduction in vivo [48,49]. Here, CXCR3 is linked to neoplasm.